Fig. 3
Cessation of anti-VLA-4 mAb treatment leads to rapid activation of microglia, which can be quantified using in vivo TSPO imaging. a A graph showing BPND calculated as a function of treatment by subtracting the day 30 BPND value from the values at the other time points. Treatment was started 30 days after the activation of the lesion, and a baseline PET/CT image was acquired. Animals were treated with subcutaneous injection of an anti-VLA-4 mAb or an isotype-matched non-binding control mAb every third day until day 61. The treatment period is shown as a light grey background. PET/CT images were acquired on days 30, 44, 65, 86 and 142. Statistical analysis indicates the difference in the mean change during the study between the treated and control animals in group A. All data are plotted as means, with the error bars showing SD values. b No changes in lesion volume were detected between treated and control animals. *p < 0.05, **p < 0.01, ***p < 0.001; BPND non-displaceable binding potential, CNS central nervous system, CT computer tomography, mAb monoclonal antibody, MRI magnetic resonance imaging, mAb monoclonal antibody, PET positron emission tomography, VLA-4 very late antigen-4